Towards the development of a pediatric ventricular assist device

Harvey S. Borovetz; Stephen Badylak; J. Robert Boston; Carl Johnson; Robert Kormos; Marina V. Kameneva; Marwan Simaan; Trevor A. Snyder; Hiro Tsukui; William R. Wagner; Joshua Woolley; James Antaki; Chenguang Diao; Stijn Vandenberghe; Bradley Keller; Victor Morell; Peter Wearden; Steven Webber; Jeff Gardiner; Chung M. Li; Dave Paden; Bradley Paden; Shaun Snyder; Jingchun Wu; Gill Bearnson; John A. Hawkins; Gordon Jacobs; John Kirk; Pratap Khanwilkar; Peter C. Kouretas; James Long; R. E. Shaddy

doi:10.3727/000000006783982304

Towards the development of a pediatric ventricular assist device

Harvey S. Borovetz^*, Stephen Badylak, J. Robert Boston, Carl Johnson, Robert Kormos, Marina V. Kameneva, Marwan Simaan, Trevor A. Snyder, Hiro Tsukui, William R. Wagner, Joshua Woolley, James Antaki, Chenguang Diao, Stijn Vandenberghe, Bradley Keller, Victor Morell, Peter Wearden, Steven Webber, Jeff Gardiner, Chung M. LiDave Paden, Bradley Paden, Shaun Snyder, Jingchun Wu, Gill Bearnson, John A. Hawkins, Gordon Jacobs, John Kirk, Pratap Khanwilkar, Peter C. Kouretas, James Long, R. E. Shaddy

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involves a consortium consisting of UoP, Children's Hospital of Pittsburgh (CHP), Carnegie Mellon University, World Heart Corporation, and LaunchPoint Technologies, Inc. The overall aim of our program is to develop a highly reliable, biocompatible ventricular assist device (VAD) for chronic support (6 months) of the unique and high-risk population of children between 3 and 15 kg (patients from birth to 2 years of age). The innovative pediatric ventricular assist device we are developing is based on a miniature mixed flow turbodynamic pump featuring magnetic levitation, to assure minimal blood trauma and risk of thrombosis. This review article discusses the limitations of current pediatric cardiac assist treatment options and the work to date by our consortium toward the development of a pediatric VAD.

Original language	English
Pages (from-to)	S69-S74
Journal	Cell Transplantation
Volume	15
Issue number	SUPPL. 1
DOIs	https://doi.org/10.3727/000000006783982304
State	Published - 2006
Externally published	Yes

Keywords

ECMO
Magnetic levitation
Turbodynamic pump
Ventricular assist device (VAD)

Access to Document

10.3727/000000006783982304

Cite this

Borovetz, H. S., Badylak, S., Boston, J. R., Johnson, C., Kormos, R., Kameneva, M. V., Simaan, M., Snyder, T. A., Tsukui, H., Wagner, W. R., Woolley, J., Antaki, J., Diao, C., Vandenberghe, S., Keller, B., Morell, V., Wearden, P., Webber, S., Gardiner, J., ... Shaddy, R. E. (2006). Towards the development of a pediatric ventricular assist device. Cell Transplantation, 15(SUPPL. 1), S69-S74. https://doi.org/10.3727/000000006783982304

@article{c9895dac9920452ba73377bd8cc9811a,

title = "Towards the development of a pediatric ventricular assist device",

abstract = "The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involves a consortium consisting of UoP, Children's Hospital of Pittsburgh (CHP), Carnegie Mellon University, World Heart Corporation, and LaunchPoint Technologies, Inc. The overall aim of our program is to develop a highly reliable, biocompatible ventricular assist device (VAD) for chronic support (6 months) of the unique and high-risk population of children between 3 and 15 kg (patients from birth to 2 years of age). The innovative pediatric ventricular assist device we are developing is based on a miniature mixed flow turbodynamic pump featuring magnetic levitation, to assure minimal blood trauma and risk of thrombosis. This review article discusses the limitations of current pediatric cardiac assist treatment options and the work to date by our consortium toward the development of a pediatric VAD.",

keywords = "ECMO, Magnetic levitation, Turbodynamic pump, Ventricular assist device (VAD)",

author = "Borovetz, {Harvey S.} and Stephen Badylak and Boston, {J. Robert} and Carl Johnson and Robert Kormos and Kameneva, {Marina V.} and Marwan Simaan and Snyder, {Trevor A.} and Hiro Tsukui and Wagner, {William R.} and Joshua Woolley and James Antaki and Chenguang Diao and Stijn Vandenberghe and Bradley Keller and Victor Morell and Peter Wearden and Steven Webber and Jeff Gardiner and Li, {Chung M.} and Dave Paden and Bradley Paden and Shaun Snyder and Jingchun Wu and Gill Bearnson and Hawkins, {John A.} and Gordon Jacobs and John Kirk and Pratap Khanwilkar and Kouretas, {Peter C.} and James Long and Shaddy, {R. E.}",

year = "2006",

doi = "10.3727/000000006783982304",

language = "English",

volume = "15",

pages = "S69--S74",

journal = "Cell Transplantation",

issn = "0963-6897",

number = "SUPPL. 1",

}

Borovetz, HS, Badylak, S, Boston, JR, Johnson, C, Kormos, R, Kameneva, MV, Simaan, M, Snyder, TA, Tsukui, H, Wagner, WR, Woolley, J, Antaki, J, Diao, C, Vandenberghe, S, Keller, B, Morell, V, Wearden, P, Webber, S, Gardiner, J, Li, CM, Paden, D, Paden, B, Snyder, S, Wu, J, Bearnson, G, Hawkins, JA, Jacobs, G, Kirk, J, Khanwilkar, P, Kouretas, PC, Long, J & Shaddy, RE 2006, 'Towards the development of a pediatric ventricular assist device', Cell Transplantation, vol. 15, no. SUPPL. 1, pp. S69-S74. https://doi.org/10.3727/000000006783982304

TY - JOUR

T1 - Towards the development of a pediatric ventricular assist device

AU - Borovetz, Harvey S.

AU - Badylak, Stephen

AU - Boston, J. Robert

AU - Johnson, Carl

AU - Kormos, Robert

AU - Kameneva, Marina V.

AU - Simaan, Marwan

AU - Snyder, Trevor A.

AU - Tsukui, Hiro

AU - Wagner, William R.

AU - Woolley, Joshua

AU - Antaki, James

AU - Diao, Chenguang

AU - Vandenberghe, Stijn

AU - Keller, Bradley

AU - Morell, Victor

AU - Wearden, Peter

AU - Webber, Steven

AU - Gardiner, Jeff

AU - Li, Chung M.

AU - Paden, Dave

AU - Paden, Bradley

AU - Snyder, Shaun

AU - Wu, Jingchun

AU - Bearnson, Gill

AU - Hawkins, John A.

AU - Jacobs, Gordon

AU - Kirk, John

AU - Khanwilkar, Pratap

AU - Kouretas, Peter C.

AU - Long, James

AU - Shaddy, R. E.

PY - 2006

Y1 - 2006

N2 - The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involves a consortium consisting of UoP, Children's Hospital of Pittsburgh (CHP), Carnegie Mellon University, World Heart Corporation, and LaunchPoint Technologies, Inc. The overall aim of our program is to develop a highly reliable, biocompatible ventricular assist device (VAD) for chronic support (6 months) of the unique and high-risk population of children between 3 and 15 kg (patients from birth to 2 years of age). The innovative pediatric ventricular assist device we are developing is based on a miniature mixed flow turbodynamic pump featuring magnetic levitation, to assure minimal blood trauma and risk of thrombosis. This review article discusses the limitations of current pediatric cardiac assist treatment options and the work to date by our consortium toward the development of a pediatric VAD.

AB - The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involves a consortium consisting of UoP, Children's Hospital of Pittsburgh (CHP), Carnegie Mellon University, World Heart Corporation, and LaunchPoint Technologies, Inc. The overall aim of our program is to develop a highly reliable, biocompatible ventricular assist device (VAD) for chronic support (6 months) of the unique and high-risk population of children between 3 and 15 kg (patients from birth to 2 years of age). The innovative pediatric ventricular assist device we are developing is based on a miniature mixed flow turbodynamic pump featuring magnetic levitation, to assure minimal blood trauma and risk of thrombosis. This review article discusses the limitations of current pediatric cardiac assist treatment options and the work to date by our consortium toward the development of a pediatric VAD.

KW - ECMO

KW - Magnetic levitation

KW - Turbodynamic pump

KW - Ventricular assist device (VAD)

UR - http://www.scopus.com/inward/record.url?scp=33745199212&partnerID=8YFLogxK

U2 - 10.3727/000000006783982304

DO - 10.3727/000000006783982304

M3 - Article

C2 - 16826798

AN - SCOPUS:33745199212

SN - 0963-6897

VL - 15

SP - S69-S74

JO - Cell Transplantation

JF - Cell Transplantation

IS - SUPPL. 1

ER -

Towards the development of a pediatric ventricular assist device

Abstract

Keywords

Access to Document

Fingerprint

Cite this